Angiogenesis in glioblastoma multiforme: Navigating the maze

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 712-718

  Linkous, Amanda G ^a   Yazlovitskaya, Eugenia M ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Division of Nephrology   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Angiogenesis; Anti angiogenic agents; Drug resistance; Glioblastoma multiforme (GBM); Signal transduction; Targeted drug therapy; Tumor vascularization

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN 4; ARGATROBAN; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; CYTOSOLIC PHOSPHOLIPASE A2; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; PENICILLAMINE; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; B LYMPHOCYTE; CALCIUM TRANSPORT; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CELL FUNCTION; CELL INTERACTION; CYTOTOXICITY; DISEASE MODEL; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LUNG CARCINOMA; METHYLATION; MOLECULAR MIMICRY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; UPREGULATION;

EID: 80053513676     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378643     Document Type: Review

References (61)

1. Dewhirst, M. W.; Cao, Y.; Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer, 2008, 8 (6), 425-437.
2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285 (21), 1182-1186.
3. Norden, A. D.; Drappatz, J.; Wen, P. Y. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol., 2009, 5 (11), 610-620.
4. El Hallani, S.; Boisselier, B.; Peglion, F.; Rousseau, A.; Colin, C.; Idbaih, A.; Marie, Y.; Mokhtari, K.; Thomas, J. L.; Eichmann, A.; Delattre, J. Y.; Maniotis, A. J.; Sanson, M. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain, 2010, 133 (Pt 4), 973-982.
5. Denysenko, T.; Gennero, L.; Roos, M. A.; Melcarne, A.; Juenemann, C.; Faccani, G.; Morra, I.; Cavallo, G.; Reguzzi, S.; Pescarmona, G.; Ponzetto, A. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem. Funct., 2010, 28 (5), 343-351.
6. Chen, Z.; Htay, A.; Dos Santos, W.; Gillies, G. T.; Fillmore, H. L.; Sholley, M. M.; Broaddus, W. C. In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by threedimensional co-culture with glioblastoma cells. J. Neurooncol., 2009, 92 (2), 121-128.
7. Weller, M. Angiogenesis in glioblastoma: just another moving target? Brain, 2010, 133 (Pt 4), 955-956.
8. Nehls, V.; Schuchardt, E.; Drenckhahn, D. The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc. Res., 1994, 48 (3), 349-363.
9. Juillerat-Jeanneret, L.; Monnet-Tschudi, F.; Zurich, M. G.; Lohm, S.; Duijvestijn, A. M.; Honegger, P. Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature. Cell Tissue Res., 2003, 311 (1), 53-59.
10. Nakatsu, M. N.; Sainson, R. C.; Aoto, J. N.; Taylor, K. L.; Aitkenhead, M.; Perez-del-Pulgar, S.; Carpenter, P. M.; Hughes, C. C. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc. Res., 2003, 66 (2), 102-112.
11. Wenger, A.; Kowalewski, N.; Stahl, A.; Mehlhorn, A. T.; Schmal, H.; Stark, G. B.; Finkenzeller, G. Development and characterization of a spheroidal coculture model of endothelial cells and fibroblasts for improving angiogenesis in tissue engineering. Cells Tissues Organs, 2005, 181 (2), 80-88.
12. Iwamoto, F. M.; Abrey, L. E.; Beal, K.; Gutin, P. H.; Rosenblum, M. K.; Reuter, V. E.; DeAngelis, L. M.; Lassman, A. B. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology, 2009, 73 (15), 1200-1206.
13. Schmidt, N. O.; Westphal, M.; Hagel, C.; Ergun, S.; Stavrou, D.; Rosen, E. M.; Lamszus, K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer, 1999, 84 (1), 10-18.
14. Plate, K. H.; Breier, G.; Weich, H. A.; Mennel, H. D.; Risau, W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer, 1994, 59 (4), 520-529.
15. Plate, K. H.; Breier, G.; Weich, H. A.; Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 1992, 359 (6398), 845-848.
16. Holash, J.; Maisonpierre, P. C.; Compton, D.; Boland, P.; Alexander, C. R.; Zagzag, D.; Yancopoulos, G. D.; Wiegand, S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999, 284 (5422), 1994-1998.
17. Soker, S.; Fidder, H.; Neufeld, G.; Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem., 1996, 271 (10), 5761-5767.
18. Iwamoto, F. M.; Fine, H. A. Bevacizumab for malignant gliomas. Arch. Neurol., 2010, 67 (3), 285-288.
19. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8 (8), 592-603.
20. Brada, M.; Hoang-Xuan, K.; Rampling, R.; Dietrich, P. Y.; Dirix, L. Y.; Macdonald, D.; Heimans, J. J.; Zonnenberg, B. A.; Bravo-Marques, J. M.; Henriksson, R.; Stupp, R.; Yue, N.; Bruner, J.; Dugan, M.; Rao, S.; Zaknoen, S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol., 2001, 12 (2), 259-266.
21. Brandes, A. A.; Ermani, M.; Basso, U.; Amista, P.; Berti, F.; Scienza, R.; Rotilio, A.; Pinna, G.; Gardiman, M.; Monfardini, S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol., 2001, 12 (2), 255-257.
22. Yung, W. K.; Albright, R. E.; Olson, J.; Fredericks, R.; Fink, K.; Prados, M. D.; Brada, M.; Spence, A.; Hohl, R. J.; Shapiro, W.; Glantz, M.; Greenberg, H.; Selker, R. G.; Vick, N. A.; Rampling, R.; Friedman, H.; Phillips, P.; Bruner, J.; Yue, N.; Osoba, D.; Zaknoen, S.; Levin, V. A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 2000, 83 (5), 588-593.
23. Scott, B. J.; Quant, E. C.; McNamara, M. B.; Ryg, P. A.; Batchelor, T. T.; Wen, P. Y. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro. Oncol., 2010, 12 (6), 603-607.
24. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y.; Jain, R. K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11 (1), 83-95.
25. Blouw, B.; Song, H.; Tihan, T.; Bosze, J.; Ferrara, N.; Gerber, H. P.; Johnson, R. S.; Bergers, G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003, 4 (2), 133-146.
26. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8 (4), 299-309.
27. Fernando, N. T.; Koch, M.; Rothrock, C.; Gollogly, L. K.; D'Amore, P.A.; Ryeom, S.; Yoon, S. S. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res., 2008, 14 (5), 1529-1539.
28. Kerbel, R. S. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell, 2005, 8 (4), 269-271.
29. Mizukami, Y.; Jo, W. S.; Duerr, E. M.; Gala, M.; Li, J.; Zhang, X.; Zimmer, M. A.; Iliopoulos, O.; Zukerberg, L. R.; Kohgo, Y.; Lynch, M. P.; Rueda, B. R.; Chung, D. C. Induction of interleukin- 8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med., 2005, 11 (9), 992-997.
30. Rubenstein, J. L.; Kim, J.; Ozawa, T.; Zhang, M.; Westphal, M.; Deen, D. F.; Shuman, M. A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia, 2000, 2 (4), 306-314.
31. Lund, E. L.; Hog, A.; Olsen, M. W.; Hansen, L. T.; Engelholm, S. A.; Kristjansen, P. E. Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma. Int. J. Cancer, 2004, 108 (6), 833-838.
32. Aghi, M.; Cohen, K. S.; Klein, R. J.; Scadden, D. T.; Chiocca, E. A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res., 2006, 66 (18), 9054-9064.
33. Du, R.; Lu, K. V.; Petritsch, C.; Liu, P.; Ganss, R.; Passegue, E.; Song, H.; Vandenberg, S.; Johnson, R. S.; Werb, Z.; Bergers, G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell, 2008, 13 (3), 206-220.
34. Allt, G.; Lawrenson, J. G. Pericytes: cell biology and pathology. Cells Tissues Organs, 2001, 169 (1), 1-11.
35. Bergers, G.; Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol., 2005, 7 (4), 452-464.
36. Guo, P.; Hu, B.; Gu, W.; Xu, L.; Wang, D.; Huang, H. J.; Cavenee, W. K.; Cheng, S. Y. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol., 2003, 162 (4), 1083-1093.
37. Erber, R.; Thurnher, A.; Katsen, A. D.; Groth, G.; Kerger, H.; Hammes, H. P.; Menger, M. D.; Ullrich, A.; Vajkoczy, P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J., 2004, 18 (2), 338-340.
38. Brem, S.; Grossman, S. A.; Carson, K. A.; New, P.; Phuphanich, S.; Alavi, J. B.; Mikkelsen, T.; Fisher, J. D. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro. Oncol., 2005, 7 (3), 246-253.
39. Mikkelsen, T.; Lush, R.; Grossman, S. A.; Carson, K. A.; Fisher, J. D.; Alavi, J. B.; Rosenfeld, S. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest. New Drugs, 2007, 25 (3), 259-263.
40. Tosato, G.; Segarra, M.; Salvucci, O. Cytosolic Phospholipase A2{alpha} and Cancer: A Role in Tumor Angiogenesis. J. Natl. Cancer Inst., 2010, 102 (18), 1377-79.
41. Linkous, A. G.; Yazlovitskaya, E. M.; Hallahan, D. E. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J. Nat. Cancer Inst., 2010, 102 (18), 1398-1412.
42. Brunckhorst, M. K.; Wang, H.; Lu, R.; Yu, Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res., 2010, 70 (18), 7283-7293.
43. Minniti, G.; Salvati, M.; Arcella, A.; Buttarelli, F.; D'Elia, A.; Lanzetta, G.; Esposito, V.; Scarpino, S.; Maurizi Enrici, R.; Giangaspero, F. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J. Neurooncol, 2011, 102 (2), 311-316.
44. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol., 2010, 28 (16), 2712-2718.
45. Hua, Y.; Tang, L.; Keep, R. F.; Schallert, T.; Fewel, M. E.; Muraszko, K. M.; Hoff, J. T.; Xi, G. The role of thrombin in gliomas. J. Thromb. Haemost., 2005, 3 (9), 1917-1923.
46. Reynes, G.; Vila, V.; Martin, M.; Parada, A.; Fleitas, T.; Reganon, E.; Martinez-Sales, V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J. Neurooncol., 2010, 102 (1), 35-41.
47. Belting, M.; Ahamed, J.; Ruf, W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler. Thromb. Vasc. Biol., 2005, 25 (8), 1545-1550.
48. Carneiro-Lobo, T. C.; Konig, S.; Machado, D. E.; Nasciutti, L. E.; Forni, M. F.; Francischetti, I. M.; Sogayar, M. C.; Monteiro, R. Q. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost., 2009, 7 (11), 1855-1864.
49. Rak, J.; Milsom, C.; May, L.; Klement, P.; Yu, J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 2006, 32 (1), 54-70.
50. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T. L.; Fuller, C.; Hamner, B.; Oh, E. Y.; Gaber, M. W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I. T.; Zakharenko, S. S.; Gajjar, A.; Davidoff, A.; Gilbertson, R. J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11 (1), 69-82.
51. Currle, D. S.; Gilbertson, R. J. The niche revealed. Cell Stem Cell, 2008, 3 (3), 234-236.
52. Gilbertson, R. J.; Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer, 2007, 7 (10), 733-736.
53. Charles, N.; Holland, E. C. The perivascular niche microenvironment in brain tumor progression. Cell Cycle, 2010, 9 (15), 3012-3021.
54. Fine, H. A. Glioma stem cells: not all created equal. Cancer Cell, 2009, 15 (4), 247-249.
55. Kotliarov, Y.; Kotliarova, S.; Charong, N.; Li, A.; Walling, J.; Aquilanti, E.; Ahn, S.; Steed, M. E.; Su, Q.; Center, A.; Zenklusen, J. C.; Fine, H. A. Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. Cancer Res., 2009, 69 (4), 1596-1603.
56. Son, M. J.; Woolard, K.; Nam, D. H.; Lee, J.; Fine, H. A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell, 2009, 4 (5), 440-452.
57. Woolard, K.; Fine, H. A. Glioma stem cells: better flat than round. Cell Stem Cell, 2009, 4 (6), 466-467.
58. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307 (5706), 58-62.
59. Macdonald, D. R.; Cascino, T. L.; Schold, S. C., Jr.; Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol., 1990, 8 (7), 1277-1280.
60. Kamoun, W. S.; Ley, C. D.; Farrar, C. T.; Duyverman, A. M.; Lahdenranta, J.; Lacorre, D. A.; Batchelor, T. T.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Fukumura, D.; Sorensen, A. G.; Jain, R. K. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol., 2009, 27 (15), 2542-2552.
61. van den Bent, M. J.; Vogelbaum, M. A.; Wen, P. Y.; Macdonald, D. R.; Chang, S. M. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J. Clin. Oncol., 2009, 27 (18), 2905-2908.